These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

955 related items for PubMed ID: 19393305

  • 1. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
    Santos-Cuevas CL, Ferro-Flores G, Arteaga de Murphy C, Ramírez Fde M, Luna-Gutiérrez MA, Pedraza-López M, García-Becerra R, Ordaz-Rosado D.
    Int J Pharm; 2009 Jun 22; 375(1-2):75-83. PubMed ID: 19393305
    [Abstract] [Full Text] [Related]

  • 2. 99mTc-N2S2-Tat (49-57)-bombesin internalized in nuclei of prostate and breast cancer cells: kinetics, dosimetry and effect on cellular proliferation.
    Santos-Cuevas CL, Ferro-Flores G, Rojas-Calderón EL, García-Becerra R, Ordaz-Rosado D, Arteaga de Murphy C, Pedraza-López M.
    Nucl Med Commun; 2011 Apr 22; 32(4):303-13. PubMed ID: 21304415
    [Abstract] [Full Text] [Related]

  • 3. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model.
    Ananias HJ, Yu Z, Dierckx RA, van der Wiele C, Helfrich W, Wang F, Yan Y, Chen X, de Jong IJ, Elsinga PH.
    Mol Pharm; 2011 Aug 01; 8(4):1165-73. PubMed ID: 21699202
    [Abstract] [Full Text] [Related]

  • 4. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S, García Garayoa E, Maes V, Brans L, Tourwé DA, Müller C, Schibli R.
    Nucl Med Biol; 2011 Oct 01; 38(7):997-1009. PubMed ID: 21982571
    [Abstract] [Full Text] [Related]

  • 5. Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics.
    Okarvi SM, Jammaz IA.
    Nucl Med Biol; 2012 Aug 01; 39(6):795-804. PubMed ID: 22381782
    [Abstract] [Full Text] [Related]

  • 6. Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives.
    Fragogeorgi EA, Zikos C, Gourni E, Bouziotis P, Paravatou-Petsotas M, Loudos G, Mitsokapas N, Xanthopoulos S, Mavri-Vavayanni M, Livaniou E, Varvarigou AD, Archimandritis SC.
    Bioconjug Chem; 2009 May 20; 20(5):856-67. PubMed ID: 19344122
    [Abstract] [Full Text] [Related]

  • 7. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
    Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, Maecke HR.
    J Nucl Med; 2005 May 20; 46(5):823-30. PubMed ID: 15872357
    [Abstract] [Full Text] [Related]

  • 8. Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties.
    Smith CJ, Gali H, Sieckman GL, Higginbotham C, Volkert WA, Hoffman TJ.
    Bioconjug Chem; 2003 May 20; 14(1):93-102. PubMed ID: 12526698
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Click chemistry for [(99m)Tc(CO)(3)] labeling of Lys(3)-bombesin.
    Ferro-Flores G, Rivero IA, Santos-Cuevas CL, Sarmiento JI, Arteaga de Murphy C, Ocampo-García BE, García-Becerra R, Ordaz-Rosado D.
    Appl Radiat Isot; 2010 Dec 20; 68(12):2274-8. PubMed ID: 20580238
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies.
    Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ.
    Nucl Med Biol; 2008 May 20; 35(4):401-11. PubMed ID: 18482677
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP.
    J Nucl Med; 2002 Dec 20; 43(12):1650-6. PubMed ID: 12468515
    [Abstract] [Full Text] [Related]

  • 17. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor.
    Parry JJ, Andrews R, Rogers BE.
    Breast Cancer Res Treat; 2007 Jan 20; 101(2):175-83. PubMed ID: 16838112
    [Abstract] [Full Text] [Related]

  • 18. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Volkert WA, Hoffman TJ.
    Anticancer Res; 2003 Jan 20; 23(1A):63-70. PubMed ID: 12680195
    [Abstract] [Full Text] [Related]

  • 19. Impact of functionalized coligands on the pharmacokinetics of 99mTcIII '4+1' mixed-ligand complexes conjugated to bombesin.
    Kunstler JU, Bergmann R, Gniazdowska E, Koźmiński P, Walther M, Pietzsch HJ.
    J Inorg Biochem; 2011 Nov 20; 105(11):1383-90. PubMed ID: 21946438
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer.
    Yu Z, Carlucci G, Ananias HJ, Dierckx RA, Liu S, Helfrich W, Wang F, de Jong IJ, Elsinga PH.
    Amino Acids; 2013 Feb 20; 44(2):543-53. PubMed ID: 22833158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.